MDACC: Leukaemia Insights
Leukaemia Insights Newsletter: MD Anderson Cancer Center.
Leukaemia Insights Newsletter: MD Anderson Cancer Center.
Leukaemia Insights Newsletter: MD Anderson Cancer Center.
Leukaemia Insights Newsletter: MD Anderson Cancer Center.
The CML Support Group says: ”Patients are angry, frightened and very frustrated by this inhumane provisional recommendation by the NICE appraisal committee- a recommendation that seems to us to have much more to do with cost cutting than with a rational appraisal of two highly effective and innovative therapies. If the recommendation is upheld, and NHS funding of these therapies is refused in cases of imatinib intolerance, it will undoubtedly cost lives. It is a shocking prospect that UK citizens, who prove to be intolerant to standard dose imatinib (Glivec) will be denied access to such effective and life-saving alternatives. Clinicians will find themselves unable to treat their patients within internationally agreed expert recommendations outlined by the European Leukaemia Network, with the knowledge that clinicians in Germany, France, the Netherlands and other EU countries, are able to offer their patients the very best therapeutic options available.
<p>
<a class="topleft" href="http://www.gopetition.com/petitions/be-nice-to-cancer-patients/sign.html... alt="GoPetition" src="http://www.gopetition.com/counters?pid=34249&t=2" title="NICE: Be NICE to Cancer Patients (powered by GoPetition)" width="206" /></a> The CML Support Group says: ”Patients are angry, frightened and very frustrated by this inhumane provisional recommendation by the NICE appraisal committee- a recommendation that seems to us to have much more to do with cost cutting than with a rational appraisal of two highly effective and innovative therapies. If the recommendation is upheld, and NHS funding of these therapies is refused in cases of imatinib intolerance, it will undoubtedly cost lives. It is a shocking prospect that UK citizens, who prove to be intolerant to standard dose imatinib (Glivec) will be denied access to such effective and life-saving alternatives. Clinicians will find themselves unable to treat their patients within internationally agreed expert recommendations outlined by the European Leukaemia Network, with the knowledge that clinicians in Germany, France, the Netherlands and other EU countries, are able to offer their patients the very best therapeutic options available.</p>
FDA Committee Favors Validated Gene Test Before Considering Targeted Therapy
Elsevier Global Medical News. 2010 Mar 22, K Wachter
Cancer groups challenge NICE ruling on Vidaza drug.
NHS watchdog NICE acting against government advice, says cancer group.
Betrayal of 20,000 cancer patients: Rationing body rejects ten drugs (allowed in Europe) that could have extended lives
By DANIEL MARTIN
Last updated at 12:10 AM on 16th March 2010
www.dailymail.co.uk/health/article-1257944/NICE-rejects-cancer-drugs-extended-patients-lives
Cancer Issues Author: Ohio State University Comprehensive Cancer Center Last Updated: Mar 4, 2010 - 4:43:44 PM
Key Cause of Chronic Leukemia Progression
By Ohio State University Comprehensive Cancer Center
Mar 4, 2010 - 4:39:45 PM
(HealthNewsDigest.com) - COLUMBUS, Ohio – Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.
I was confused by the use of the word 'slates' in this context... but I worked out that it probably means 'includes - as in 'writes on the slate' -rather than in the usual UK English meaning of to slate = to rubbish.... so 'FDA slates' is a good thing ;o)
Sign here to petition NICE and the DoH
www.gopetition.co.uk/online/34249.html
JCO Early Release, published online ahead of print Feb 8 2010
Journal of Clinical Oncology, 10.1200/JCO.2009.25.5075